Search results for " coagulation"

showing 10 items of 221 documents

Neonatal outcome following long-distance air travel for fetoscopic laser coagulation treatment of twin-to-twin transfusion syndrome

2011

Abstract Objective To investigate the impact of undertaking long-distance air travel to a specialized medical center while pregnant in order to undergo fetoscopic laser coagulation (FLC) for twin-to-twin transfusion syndrome (TTTS). Methods A retrospective cohort study was conducted of women with TTTS who travelled by air (n = 16) or land (n = 61) to the Centre of Perinatal Diagnosis and Microinvasive Fetal Surgery, Mainz, Germany, between January 1, 2006, and December 31, 2010. All women underwent FLC on arrival at the study center. Neonatal outcome, postoperative neonatal survival rates, and rates of adverse effects were recorded. Results The postoperative survival rate for a single twin …

Adultmedicine.medical_specialtyAircraftmedicine.medical_treatmentTwin-to-twin transfusion syndromeFetoscopyMonochorionic twin pregnancyFetoscopic laser coagulationPregnancyGermanyMedicineHumansTertiary care medical centerAdverse effectSurvival rateRetrospective StudiesPregnancyAir PressureTravelLaser Coagulationmedicine.diagnostic_testbusiness.industryObstetricsFetal surgeryFetoscopyTwin-to-twin transfusion syndromeInfant NewbornObstetrics and GynecologyRetrospective cohort studyGeneral MedicineFetofetal Transfusionmedicine.diseaseSurvival RateTreatment OutcomePregnancy TwinFemalebusinessLaser coagulationAir travelInternational Journal of Gynecology & Obstetrics
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY

2008

Summary.  Background: Combined vitamin K-dependent clotting factor (VKCF) deficiency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene. Methods and results: An Italian patient with moderate to severe bleeding tendency was genotyped, and found to be homozygous for the unique VKORC1 mutation (Arg98Trp) so far detected in VKCFD2. The activity levels of VKCFs were differentially reduced, and inversely related to the previously estimated affinity of procoagulant factor propeptides for the γ-carboxylase. The normal (factor IX) or reduced antigen levels (other VKCFs) produced a gradient in specific activities. Vitamin K su…

Adultmedicine.medical_specialtycoagulation factor levelsVitamin KProtein SMixed Function OxygenasesTissue factorchemistry.chemical_compoundInternal medicineVitamin K Epoxide ReductasesmedicineVKCFD2HumansFactor IXClotting factorCoagulation factor levels; Thrombin generation; Vitamin K supplementation; VKCFD2; VKORC1 mutation;biologyFactor VIIChemistryFactor XHomozygotevitamin K supplementationHematologyBlood Coagulation DisordersEndocrinologyTreatment OutcomeCoagulationthrombin generationImmunologyMutationbiology.proteinFemaleBlood Coagulation TestsVKCFD2 VKORC1 mutation coagulation factor levels thrombin generation vitamin K supplementationProtein Cmedicine.drugHalf-LifeVKORC1 mutation
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct

Association of Inflammation Markers with Impaired Insulin Sensitivity and Coagulative Activation in Obese Healthy Women

2003

Abstract Insulin resistance is associated with a low chronic inflammatory state. In this study we investigated the relationship between impaired insulin sensitivity and selected markers of inflammation and thrombin generation in obese healthy women. We examined 32 healthy obese women (body mass index ≥ 28), with normal insulin sensitivity (NIS, n = 14) or impaired insulin sensitivity (n = 18), and 10 nonobese women (body mass index < 25). Impaired insulin sensitivity patients had significantly higher levels of C-reactive protein (CRP), TGF-β1, plasminogen activator inhibitor-1 (PAI-1), activated factor VII (VIIa), and prothrombin fragment 1 + 2 (F1 + 2) compared with either control s…

Adultmedicine.medical_specialtyobesityEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryPopulationInflammationFactor VIIaBiologyBiochemistryEndocrinologyInsulin resistanceTransforming Growth Factor betaInternal medicineinsulin resistancePlasminogen Activator Inhibitor 1medicineHumansProtein PrecursorseducationBlood CoagulationPancreatic hormoneeducation.field_of_studyInsulinBiochemistry (medical)ThrombinMiddle Agedmedicine.diseaseObesityPeptide FragmentsC-Reactive ProteinEndocrinologyhemostasis; inflammation; insulin resistance; obesityinflammationhemostasisFemaleProthrombinmedicine.symptomBody mass indexPlasminogen activatorBiomarkers
researchProduct

Successful treatment of gallstone ileus (Bouveret's syndrome) by using extracorporal shock wave lithotripsy and argon plasma coagulation.

2006

Aged 80 and overmedicine.medical_specialtyS syndromeLaser Coagulationbusiness.industryGastric Outlet ObstructionGastroenterologyArgon plasma coagulationShock wave lithotripsyGallstonesSyndromeSurgeryRadiographyIleusLithotripsyGallstone ileusmedicineHumansRadiology Nuclear Medicine and imagingFemaleEndoscopy Digestive SystemArgonbusinessGastrointestinal endoscopy
researchProduct

Coagulation signaling and cancer immunotherapy.

2019

The last decades have delineated many interactions of the hemostatic system with cancer cells that are pivotal for cancer-associated thrombosis, angiogenesis and metastasis. Expanding evidence shows that platelets, the tissue factor pathway, and proteolytic signaling involving protease-activated receptors (PARs) are also central players in innate and adaptive immunity. Recent studies in immune-competent mice have uncovered new immune-evasive roles of coagulation signaling networks in the development and growth of different preclinical tumor models. Tumor-type specific PAR1 signaling facilitates the escape from immune surveillance by cytotoxic T cells. In addition, tumor-associated macrophag…

Angiogenesismedicine.medical_treatmentReceptors Proteinase-ActivatedMacrophage polarization030204 cardiovascular system & hematology03 medical and health sciencesMice0302 clinical medicineCancer immunotherapyNeoplasmsmedicineAnimalsBlood CoagulationTumor microenvironmentInnate immune systembusiness.industryHematologyAcquired immune systemTumor antigen030220 oncology & carcinogenesisFactor XaCancer researchImmunotherapySignal transductionbusinessSignal TransductionThrombosis research
researchProduct

Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.

2020

: ACE2 receptor has a broad expression pattern in the cellular membrane and provides a protective action against the development of cardiovascular diseases. Recently, this enzyme has become of extreme interest during the pandemic infection of COVID-19 (coronavirus disease 2019). This virus invades alveolar epithelium and cardiomyocytes using ACE2 as a transmembrane receptor. ACE2 is a counter-regulatory peptide that degrades Ang II into Ang 1-7, thereby attenuating the biological effects of the AT1 receptor. The binding between the spike protein of COVID-19 and the enzyme is crucial for the virus to enter the target cells, but whether an increase in ACE2 activity could facilitate the infect…

Angiotensin receptorARDSMyocarditisPneumonia ViralAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPharmacologyPeptidyl-Dipeptidase AVirusSettore MED/11Renin-Angiotensin System03 medical and health sciencesAngiotensin Receptor AntagonistsBetacoronavirus0302 clinical medicinemedicineHumans030212 general & internal medicineReceptorPandemicsDisseminated intravascular coagulationAngiotensin II receptor type 1business.industrySARS-CoV-2COVID-19General MedicineVirus Internalizationmedicine.diseaseCardiovascular DiseasesAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Cardiology and Cardiovascular MedicinebusinessCoronavirus Infectionshormones hormone substitutes and hormone antagonistsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Myopathic form of arthrogryposis and microcirculation lesion.

1989

A microvascular lesion characterized by extensive platelet aggregation, thrombosis, vascular damage with hemorrhages was found in the muscle of a 2-month-old boy with a myopathic form of the arthrogryposis syndrome. The lesion morphologically resembled the vascular leakage seen in immunologically mediated tissue injury. A degradative effect of proteases released during platelet and neutrophil aggregation on the muscle and joints is suggested.

ArthrogryposisArthrogryposisMalePathologymedicine.medical_specialtyVascular diseasebusiness.industryMusclesInfantAnatomyBlood Coagulation Disordersmedicine.diseaseThrombosisPathophysiologyMicrocirculationLesionNeurologyMuscular DiseasesmedicineHumansPlateletNeurology (clinical)medicine.symptombusinessNeutrophil aggregationJournal of the neurological sciences
researchProduct